Isis antisense drug lowers triglycerides; Phase III ongoing

Isis Pharmaceuticals has one Phase III clinical trial under way with a second late-stage trial expected to start before the end of 2015 for its antisense drug volanesorsen (ISIS-APOCIIIRx), which was able to significantly lower patients' triglyceride levels in a Phase II study.